commonly observed in myelofibrosis patients treated with JAK inhibitors?
Finally, what is the relationship between desialyation and the intrinsic apoptosis pathway, another mechanism known to regulate platelet life span 10 ? Serum TPO levels in mice with mutations in the apoptotic pathway are broadly consistent with the constitutive model. For example, mice with a megakaryocyte specific deletion of the anti-apoptotic protein Bcl-x L , exhibit severe thrombocytopenia owing to platelet life span being reduced to a matter of hours 11 . Megakaryopoiesis is dramatically expanded in these mice and, as would be expected in a setting of chronically elevated platelet production, TPO levels are profoundly reduced. This would suggest that apoptotic platelet clearance is mediated by a mechanism other than the AMR and is not sensed by the liver.
TPO regulation. Hepatic TPO mRNA expression was reduced by ~45% in Asgr2 −/− mice, indicating that more than half the liver's TPO expression is independent of desialylated platelet sensing. It will be of interest to understand the circumstances in which this pathway is perturbed. The function of the AMR in clearing desialylated platelets during S. pneumoniae infection suggests a role in host defense 9 , but what about other pathophysiological settings, such as essential thrombocythemia? Which endogenous sialidases are involved in modifying platelets as they age? There are four mammalian sialidase enzymes (Neu1-Neu4), and the work of Grozovsky et al. 11 suggests that one or more of these modulate the survival of circulating platelets. Are these enzymes deregulated in human disease? Furthermore, does inhibition of JAK-STAT signaling from the AMR contribute to the thrombocytopenia Whether additional sensing mechanisms exist that influence platelet biogenesis and/or life span remains to be determined. The work of Grozovsky et al. 7 paves the way to a much more nuanced understanding of the regulation of platelet homeostasis.
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The author declares no competing financial interests. npg peptides to CD4 + T cells ( Fig. 1) . If a CD4 + T cell recognizes a neoepitope, it will secrete cytokines, particularly interferon (IFN)-γ, which can be detected at the single-cell level using sensitive ELISA and flow cytometry assays. One of the innovations that was crucial for the success of this study is the manner in which B cells were expanded. Typically, human B cells are immortalized by infecting them with Epstein-Barr virus, the virus that causes infectious mononucleosis. The authors show that this approach causes IFN-γ secretion by some CD4 + T cells used in the screening assay, masking the IFN-γ signal from CD4 + T cells responding to the neoepitope 2 . To overcome this limitation, Linnemann et al. 2 grew large numbers of B cells by retrovirally expressing the oncogene encoding BCL-6 and the antiapoptotic gene encoding BCL-XL, and this prevented undue stimulation of CD4 + T cells in the screening assay.
By using this approach, the authors identified neoepitope-specific CD4 + T cells in two out of three melanoma patients 2 . The patients' T cells only recognized neoepitopes from the host's tumor, and they preferentially or exclusively recognized the neoepitope over the corresponding native, nonmutated peptide, demonstrating the exquisite specificity of the CD4 + T cells. The same approach was then applied to two additional individuals who had experienced a partial and complete
In cancer, so-called neoepitope peptides are derived from proteins encoded by mutated genes. Recent advances in next-generation DNA and RNA sequencing now enable rapid mapping of all expressed mutated genes in an individual tumor, and it is possible to predict epitopes that are efficiently presented on the surface of cancer cells. Thus, it has been demonstrated that CD8 + T cells in human melanomas are able to recognize one or more neoepitopes from mutant proteins unique to that specific melanoma. However, efficient methods for studying CD4 + T cells that recognize neoepitopes arising from somatic mutations in cancer have been lacking. In this issue of Nature Medicine, Linnemann et al. 2 describe a novel screening platform to systematically search for neoepitope-specific CD4 + T cells in five people with metastatic cutaneous melanoma, a cancer that is typically rich in mutations (Fig. 1) . Using this assay, they detect neoepitope-specific CD4 + T cells in melanoma tumors from four of the five subjects they studied.
Linnemann et al. 2 first purified and expanded CD4 + T cells from three melanoma tumors in vitro. They carried out DNA and RNA sequencing of each tumor, and synthesized all neoepitope peptides encoded by mutated sequences. The peptides were then incubated with B cells derived from the same patients as the tumors, which are able to efficiently present cancer regression, respectively, after infusion of in vitro-expanded T cell cultures 2 . CD4 + T cells from these cultures also recognized neoepitopes. The neoepitope-specific CD4 + T cells were detectable in the blood of these patients for weeks and months after, but not before, T cell infusion.
The five tumors studied encoded between 99 and 582 neoepitopes, but they contained detectable numbers of CD4 + T cells specific for only 0-3 neoepitopes, suggesting that a substantive CD4 + T cell response to a given neoepitope is rare (~0.5% of neoepitopes), as observed for CD8 + T cells 3 . In addition, the number of unique T cell clones-bearing a unique T cell receptor recognizing a specific neoepitope-was fewer than ten per recognized neoepitope, indicating that only very few of each person's naive CD4 + T cells spontaneously responded to each neoepitope. Recognized neoepitopes were unique to each individual, and the tumor from which no neoepitope-specific CD4 + T cells could be isolated had the lowest number of mutations. This suggests a possible correlation between mutational load and the probability of inducing neoepitope-specific CD4 + T cells, a notion recently supported by data on neoepitope-specific CD8 + T cells 4 .
CD4 + T cells can cause cancer regression through direct killing of cancer cells, by altering the tumor-promoting function of cells in the surrounding tumor microenvironment, and by facilitating the induction, function and tumor infiltration of cancer-specific CD8 + T cells 5 . Indeed, infusion of CD4 + T cells that recognized NY-ESO-1, a protein encoded by a nonmutated gene frequently overexpressed in cancer cells, was followed by the complete cure of a patient with metastatic melanoma 6 . Similarly, CD4 + T cells that recognize a neoepitope encoded by mutated ERBB2IP (encoding ERBB2-interacting protein) were isolated from metastatic cholangiosarcoma, grown to large numbers in vitro and returned to the patient, resulting in dramatic tumor shrinkage 7 . These studies show that cancerspecific CD4 + T cells can cause human tumor regression, adding to the importance of the findings by Linnemann et al. 2 .
The ability to detect neoepitope specific CD4 + T cells now allows validation of the hypothesis that the presence of neoepitope-specific CD4 + T cells in human tumors correlates with overall clinical outcome. This could be used to predict response to immunotherapies that are thought to be mediated at least in part by CD4 + T cells, such as interleukin-2, anti-CTLA-4, and possibly anti-PD-1. However, CD4 + T cells can assume many different phenotypes, each with distinct pro-or anti-tumor functions, and so better characterization of these cells, freshly Notwithstanding its modest sample size of five individuals, the finding of Linnemann et al. 2 that neoepitope-specific CD4 + T cells are commonly present in people with melanoma opens a gateway to a deeper understanding of the interaction between cancer and the immune system, and to harnessing this interaction into novel cancer therapies.
to remotely control expression of an insulinencoding transgene in a diabetic mouse, thereby restoring glucose homeostasis. The switch in this system (Fig. 1a) is a genetically encoded ferritin-iron-nanoparticle co-expressed with an epitope-tagged transient receptor potential vanilloid 1 fusion protein (TRPV1) Ca 2+ channel that allows regulated Ca 2+ influx triggered by either low-frequency radio waves or magnetic fields. More specifically, the genetically encoded iron oxide-containing nanoparticles are synthesized intracellularly as a GFP-tagged fusion of ferritin heavy and light chains, and the TRPV1 Ca 2+ channel is tagged with an epitope that binds GFP. Upon stimulation with radio waves or magnetic fields, the GFP-tagged iron nanoparticles that are tethered to the anti-GFP-tagged TRPV1 Ca 2+ channel activate the Ca 2+ channel, which leads to an increase in cytoplasmic free Ca 2+ concentration ([Ca 2+ ] i ). The authors first tested the efficiency of three different constructs encoding the ferritin-nanoparticles on TRPV1 activation in vitro; the constructs differed in their expression at different intracellular locations: in A major goal in biomedical research is to establish mechanisms for controlling gene expression and cellular activity in a living organism in a noninvasive manner. One way to tightly control gene expression and availability of proteins in a time-and location-dependent way is to establish a precise and efficient endogenous switch mechanism. Although photoactivation of caged compounds or genetically encoded light sensors, as in optogenetics, allows for rapidly turning signals on or off, truly noninvasive applications of this approach are restricted to accessible tissues such as the skin or the eye. To access deeper tissue, probes are required to allow light to reach the target area. Other noninvasive strategies include chemical regulation of gene expression, by insertion of tetracycline-dependent activators or repressors 1 and mutant estrogen receptor ligand binding domains that can be switched on or off by administration of synthetic estrogens 2 . However, compared with lightactivation systems, drug-regulated gene expression systems are slow and imprecise. Whereas switching on gene expression in such a system can be titrated by dose, time and mode of drug administration, switching off is dependent on the turnover of the drug and is thus difficult to control. In this issue of Nature Medicine, Stanley et al. 3 present an elegant solution to the problem of noninvasively controlling gene expression in a living animal.
Previous work by the authors led to the design of a nanoparticle-based switch, which can be applied exogenously to regulate gene expression in vivo, or endogenously produced to regulate gene expression in vitro 4 . The present study validates the use of a genetically engineered nanoparticle system in vivo and uses it Endogenous expression of tailored nanoparticles in cells followed by application of low-frequency radio waves or a magnetic field can be used to noninvasively modulate gene expression. This approach successfully induces insulin transgene expression in diabetic mice.
isolated and without culturing, is needed. To be applied therapeutically, neoepitope-specific CD4 + T cells could be isolated from tumors or peripheral blood, grown to large numbers in vitro by stimulation with relevant epitopes and returned to the patient for personalized tumor therapy. In addition, the genes encoding the neoepitope-specific TCR could be isolated and expressed in normal, blood-derived CD4 + T cells to create large numbers of genetically engineered, cancer-specific CD4 + T cells for therapy. Finally, person-specific neoepitopes could be formulated into vaccines for the activation of the neoepitope-specific CD4 + T cells already present. Such vaccines will be less cumbersome to manufacture than cell-based therapies, but owing to their modest potency thus far they may be particularly useful in settings of minimal residual disease, for example after surgery 8 .
A remaining question is whether a tumor's mutational burden correlates with its probability to induce neoepitope-specific CD4 + T cells. Cutaneous melanoma, the tumor type studied by Linnemann et al. 2 , appears to be the most mutated of all human cancers, mainly as a result of UV-radiation-induced mutations. It is possible that the intensity of immune responses to mutations will correlate with mutational burden, but it remains unclear to what extent T cell immunity to neoepitopes is influenced by the biology of individual tumors, including tumor-induced immunosuppression, and by immune perturbations caused by many conventional cancer therapies. Furthermore, can neoepitope-specific T cells be reliably identified in peripheral blood? How often and how powerfully do T cells recognize neoepitopes versus peptide epitopes derived from nonmutated proteins? Also, which of these responses is better at shrinking tumors without attacking normal tissues? And how frequently do CD4 + T cells recognize peptides containing posttranslational modifications 9 ? npg
